KaydedilenlerDerginizi ekleyin

Dergiler / Atlas Journal of Medicine / 2026 / Cilt: 6 Sayı: Özel Sayı 1 Özel Sayı

Hormon pozitif her2 negatif meme kanserinde neoadjuvan ve adjuvan tedavi seçenekleri

Neoadjuvant and Adjuvant Treatment Options in Hormone Positive Her2 Negative Breast Cancer

Seval Ay Ersoy(UNIVERSITY OF HEALTH SCIENCES, İSTANBUL KARTAL DR. LÜTFİ KIRDAR HEALTH RESEARCH CENTER)0000-0002-7555-2657
Sayfa
35–39
Yayın Tarihi
2026-05-08
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Hormon reseptör pozitif insan epidermal büyüme fakrörü 2 (Her 2) negatif meme kanserleri de bu bağlamda ayrıca değerlendirilmelidir.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Meme kanseri kadınlar arasında en sık görülen kanser olmaya devam etmektedir.
📊
Temel Bulgular & Veri:Tanı ve tedavideki gelişmelere rağmen hala pek çok hasta ileri evrede tanı almakta ve bu hastalarda tedaviye neoadjuvan kemoterapi (NAK) ile başlanmaktadır.
💡
Sonuç & Katkı:Hormon reseptör pozitif insan epidermal büyüme fakrörü 2 (Her 2) negatif meme kanserleri de bu bağlamda ayrıca değerlendirilmelidir.
🔬Tür:Derleme
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:meme kanseri · neoadjuvan tedavi · adjuvan tedavi

Özet

Meme kanseri kadınlar arasında en sık görülen kanser olmaya devam etmektedir. Tanı ve tedavideki gelişmelere rağmen hala pek çok hasta ileri evrede tanı almakta ve bu hastalarda tedaviye neoadjuvan kemoterapi (NAK) ile başlanmaktadır. NAK ile amaç bir yandan tümör boyutunu küçültüp aksilladaki metastatik lenf nodu sayısını azaltarak hastayı cerrahiye uygun hale geitrmek, öte yandan da tümörün kemoterapi yanıtını daha erken görmeyi sağlamaktır. Meme kanseri heterojen bir grup olduğu için kemoterapi yanıtı da alt gruplar arasında değişkenlik gösterir. Hormon reseptör pozitif insan epidermal büyüme fakrörü 2 (Her 2) negatif meme kanserleri de bu bağlamda ayrıca değerlendirilmelidir.

Abstract

Breast cancer remains the most common cancer among women. Despite advances in diagnosis and treatment, many patients are still diagnosed at an advanced stage and are treated with neoadjuvant chemotherapy (NAC). The aim of NAC is to reduce the size of the tumor and the number of metastatic lymph nodes in the axilla, making the patient suitable for surgery, while providing an earlier response to chemotherapy. Since breast cancer is a heterogeneous group, the response to chemotherapy varies between subgroups. Hormone receptor positive human epidermal growth factor 2 (Her 2) negative breast cancers should also be evaluated in this context.

🔖

Bu Makaleye Atıf Yap

Ersoy, S. A. (2026). Hormon pozitif her2 negatif meme kanserinde neoadjuvan ve adjuvan tedavi seçenekleri. Atlas Journal of Medicine, Cilt: 6 Sayı: Özel Sayı 1 Özel Sayı, 35–39. https://doi.org/10.54270/atljm.2026.117

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (22)

  1. Siegel RL., Kratzer TB.,et all Cancer statistics, 2025 CA: A cancer Journal for Clinicians (2025) 75:45-10
  2. von Minckwitz, G. et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J. Clin. Oncol.28, 2015–202
  3. Ogston KN, Miller ID, Payne S, et al A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320–7
  4. Hammond ME, Hayes DF, Dowsett M, et al American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907–22
  5. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 152483–24931997
  6. Cantini L, Trapani D, Guidi L, Boscolo Bielo L, Scafetta R, Koziej M, Vidal L, Saini KS, Curigliano G. Neoadjuvant therapy in hormone Receptor-Positive/ HER2-Negative breast cancer. Cancer Treat Rev. 2024 Feb;123:102669
  7. Kim HJ, Noh WC, Lee ES, et al. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Res. 2020;22:54
  8. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer Cancer 110244–2542007
  9. Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana S, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer. Clin Cancer Res. 2020 Feb 1;26(3):566-580
  10. Cheang MCU, Rimawi M, Johnston S, Jacobs SA, Bliss J, Pogue-Geile K, Kilburn L, Zhu Z, Schuster EF, Xiao H, Swaim L, Deng S, Lu DR, Gauthier E, Tursi J, Slamon DJ, Rugo HS, Finn RS, Liu Y. Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies. NPJ Breast Cancer. 2024 Jun 29;10(1):54
  11. Fjermeros K, Ghannoum S, Geisler SB, Bhargava S, Tahiri A, Klajic J, Lüders T, Fongård M, Nawaz MS, Bosnjak-Olsen T, Buvarp UE, Rosenskiold AKJ, Nguyen NT, Sletbak TT, Seyedzadeh M, Selsås K, Porojnicu AC, Skjerven HK, Hovda T, Sahlberg KK, Torland LA, Lyngra M, Hammarström CL, Hönigsperger EB, Noone JC, Mathiassen S, Hurtado A, Goel S, Koff A, Tekpli X, Kristensen VN, Geisler J. The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer. Future Oncol. 2024;20(32):2457-2466.
  12. Cottu P, D’Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat- Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Callens C, Gentien D, Lemonnier J, Vincent-Salomon A, Delaloge S. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018 Dec 1;29(12):2334-2340
  13. Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020 Jan;21(1):33-43
  14. Schlam I, Corti C, Sammons S, Mittendorf EA, Tolaney SM. Checkpoint inhibition for early-stage hormone receptor-positive breast cancer. Expert Opin Biol Ther. 2024 Jun;24(6):511-520
  15. Han R, Brogi E, Thompson D, El-Tamer M, Morrow M, Wen HY. Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience. Breast Cancer Res Treat. 2025 Mar 3
  16. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2
  17. Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol. 2019 Jan 10;37(2):105-114
  18. Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 Mar 1;41(7):1370-1375
  19. Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul;16(7):848-58
  20. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020 Dec 1;38(34):3987-3998
  21. Slamon DJ, Fasching PA, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, Bardia A, Im SA, Yardley DA, Untch M, Huang CS. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol. 2023 May 29;15:17588359231178125. doi: 10.1177/17588359231178125. Erratum in: Ther Adv Med Oncol. 2023 Sep 29;15:17588359231201818
  22. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec;33(12):1250-1268